Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Clinical Study of JAN101 for Treatment of COVID-19 Vascular Inflammation

Next Previous
X
Search
Trial Profile

A Phase 2b Clinical Study of JAN101 for Treatment of COVID-19 Vascular Inflammation

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium nitrite (Primary)
  • Indications COVID 2019 infections; Inflammation; Vascular disorders
  • Focus Adverse reactions
  • Sponsors JanOne

    • Most Recent Events

    • 24 Sep 2020 According to a JanOne media release, the Company has started production of JAN101 under Current Good Manufacturing Practices (cGMP) for the companys anticipated Phase 2b trials to treat Peripheral Artery Disease (PAD; CTP 315594) and as a potential treatment for Covid-19 vascular complications (CTP 327081).
    • 28 Aug 2020 New trial record
    • 26 Aug 2020 According to a JanOne media release, company expects to submit the investigational new drug (IND) for the treatment of Covid-19 vascular complications in the coming weeks and continues to advance plans to scale-up production of JAN101. The company will be in a position to start patient trials immediately once they gain FDA approval for the Covid-19 study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top